ArticleslgStudy

science

Zanidatamab

Zanidatamab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Zanidatamab rather than just read about it. In short: Zanidatamab, sold under the brand name Ziihera, is a humanized monoclonal antibody used for the treatment of HER2-positive biliary tract cancer. It is an IgG-like bispecific HER2-directed antibody directed against two non-overlapping domains of HER2.

Key takeaways

  • Zanidatamab belongs to science; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Zanidatamab to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Zanidatamab from memory before moving on to harder problems.

Reference excerpt

Zanidatamab, sold under the brand name Ziihera, is a humanized monoclonal antibody used for the treatment of HER2-positive biliary tract cancer. It is an IgG-like bispecific HER2-directed antibody directed against two non-overlapping domains of HER2. Zanidatamab is produced in Chinese hamster ovary cells. The most common adverse reactions include diarrhea, infusion-related reaction, abdominal pain, and fatigue. Zanidatamab was approved for medical use in the United States in November 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses Zanidatamab is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test.

Adverse effects The US Food and Drug Administration prescribing information contains a boxed warning for embryo-fetal toxicity. The most common adverse reactions include diarrhea, infusion-related reactions, abdominal pain, and fatigue.

History Efficacy was evaluated in HERIZON-BTC-01 (NCT04466891), an open-label multicenter, single-arm trial in 62 participants with unresectable or metastatic HER2-positive (IHC3+) biliary tract cancer. Participants were required to have received at least one prior gemcitabine-containing regimen in the advanced disease setting. The US Food and Drug Administration (FDA) granted the application for zanidatamab priority review, breakthrough therapy, and orphan drug designations.

Society and culture

Legal status Zanidatamab was approved for medical use in the United States in November 2024. In April 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Ziihera, intended for the treatment of adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer. The applicant for this medicinal product is Jazz Pharmaceuticals Ireland Limited. Zanidatamab was authorized for medical use in the European Union in June 2025.

Names Zanidatamab is the international nonproprietary name. Zanidatamab is sold under the brand name Ziihera.

References

External links "Zanidatamab-hrii". NCI Drug Dictionary. "Zanidatamab (Code C130010)". NCI Thesaurus. Archived from the original on 16 April 2025. Clinical trial number NCT04466891 for "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Zanidatamab

Start with the simplest possible case. Write down what Zanidatamab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Zanidatamab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Zanidatamab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Zanidatamab

In research
Zanidatamab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Zanidatamab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Zanidatamab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antineoplastic drugs, Monoclonal antibodies for tumors, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life
Look for Zanidatamab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Zanidatamab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Zanidatamab in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Zanidatamab means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Zanidatamab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Zanidatamab in simple terms?

Zanidatamab, sold under the brand name Ziihera, is a humanized monoclonal antibody used for the treatment of HER2-positive biliary tract cancer. It is an IgG-like bispecific HER2-directed antibody directed against two non-overlapping domains of HER2.

Why does Zanidatamab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Zanidatamab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Zanidatamab.

Tags

  • Antineoplastic drugs
  • Monoclonal antibodies for tumors
  • Orphan drugs

Keep exploring